Gapping down
In reaction to disappointing earnings/guidance: KSU -4.2%, FMSA -3.5%
Other news: MEIP -65.9% (announces top-line data from a randomized Phase II clinical study of Pracinostat in combination with azacitidine), IMMR -9.4% (announces settlement and license agreement With HTC Corporation (HTCKF) to resolve patent litigation), VRTX -7.1% (announces data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation), FINL -5.7% (unfavorable commentary on Friday's Mad Money), CERU -3.6% (appoints Chris Guiffre President and CEO), LULU -3% (still checking; worth noting several analysts out on name ahead of earnings this Thursday), GILD -2.4% (following reports of issues and a death related to its Harvoni Hep C drug taken in combination with amiodarone), SHPG -1.5% (may be down in symp with other bio/pharma names), GSK -1.4% (may be down in symp with other bio/pharma names), MNKD -1.1% (may be down in symp with other bio/pharma names), ARMH -1.1% (still checking), ABBV -0.7% (AbbVie (ABBV), which has a competing HCV drug Viekira with GILD), ACHN -0.5% (unfavorable commentary on Friday's Mad Money)
Analyst comments: NVDA -2.8% (downgraded to Sell from Neutral at Goldman), CCL -2.3% (downgraded to Hold at Deutsche Bank), OLN -1.8% (downgraded to Sell from Neutral at UBS), BIIB -1.8% (downgraded to Hold from Buy at Stifel), PRGO -1.6% (downgraded to Sector Perform at RBC Capital Mkts), NTAP -1.5% (downgraded to Neutral from Overweight at Piper Jaffray), EMC -1.1% (downgraded to Neutral from Overweight at Piper Jaffray)
In reaction to disappointing earnings/guidance: KSU -4.2%, FMSA -3.5%
Other news: MEIP -65.9% (announces top-line data from a randomized Phase II clinical study of Pracinostat in combination with azacitidine), IMMR -9.4% (announces settlement and license agreement With HTC Corporation (HTCKF) to resolve patent litigation), VRTX -7.1% (announces data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation), FINL -5.7% (unfavorable commentary on Friday's Mad Money), CERU -3.6% (appoints Chris Guiffre President and CEO), LULU -3% (still checking; worth noting several analysts out on name ahead of earnings this Thursday), GILD -2.4% (following reports of issues and a death related to its Harvoni Hep C drug taken in combination with amiodarone), SHPG -1.5% (may be down in symp with other bio/pharma names), GSK -1.4% (may be down in symp with other bio/pharma names), MNKD -1.1% (may be down in symp with other bio/pharma names), ARMH -1.1% (still checking), ABBV -0.7% (AbbVie (ABBV), which has a competing HCV drug Viekira with GILD), ACHN -0.5% (unfavorable commentary on Friday's Mad Money)
Analyst comments: NVDA -2.8% (downgraded to Sell from Neutral at Goldman), CCL -2.3% (downgraded to Hold at Deutsche Bank), OLN -1.8% (downgraded to Sell from Neutral at UBS), BIIB -1.8% (downgraded to Hold from Buy at Stifel), PRGO -1.6% (downgraded to Sector Perform at RBC Capital Mkts), NTAP -1.5% (downgraded to Neutral from Overweight at Piper Jaffray), EMC -1.1% (downgraded to Neutral from Overweight at Piper Jaffray)